[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neonatal-morbidity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neonatal-morbidity":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,59,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":40,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100613200","prior-study-pre-eclampsia-risk-in-oocyte-recipients-100613200",false,"NCT07263490","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) - Investigating Matching, Biomarkers and Outcomes.","PRIOR","Inclusion Criteria:\n\n* Age \\> 18 years\n* BMI \\\u003C 35 kg\u002Fm2\n* Normal wet smear within the past three years\n* Both nulli- and multiparous\n* Singletons and multiple gestations\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* BMI \\> 35 kg\u002Fm2\n* HIV\u002F hepatitis\n* Essential hypertension\n* Chronic kidney disease\n* Undiagnosed vaginal bleeding\n* Uterine malformations\n* Persisting ovarian cysts\n* Tumors in hypothalamus, pituitary, thyroid, or adrenal glands.\n* Previous breast cancer\n* Known BRCA 1 or 2 gene\n* Unregulated thyroid disease\n* Cardiovascular disease\n* Breast feeding\n* Present or previous chemotherapy\u002Fradiation therapy\n* Present or previous malignant disease\n* Smoking\n* Alcohol\u002Fdrug abuse","FEMALE","18 Years",{"count":20,"type":21},462,"ESTIMATED","OBSERVATIONAL","The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes.\n\nParticipants will be followed throughout pregnancy with blood samples, blood pressure, clinical controls and ultrasound examinations. Clinical outcomes will be registered post-partum.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Pre-eclampsia","Oocyte Donation","Pre-Eclampsia; Complicating Pregnancy","Pre-Eclampsia; Mild","Pre-Eclampsia, Severe","Pre-eclampsia or Eclampsia With Pre-existing Hypertension","ART","Neonatal Morbidity","Neonatal Mortality","Placental Abruption","Gestational Diabetes","Preterm Labor","Post-partum Hemorrhage (PPH)","Intrauterine Growth Restriction (IUGR)","Hypertensive Disorders of Pregnancy",[25,41,31,42,43,44,45],"Preeclampsia","Gestational hypertension","Oocyte donation","Egg donation","Gamete donation","RECRUITING","2026-04-07",{"date":49,"type":50},"2026-04-13","ACTUAL",{"date":52,"type":50},"2024-10-21",{"date":54,"type":21},"2028-06-01",{"name":56,"class":57},"Copenhagen University Hospital, Hvidovre","OTHER",6,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100588482","partnering-with-antenatal-navigators-to-transform-health-in-pregnancy-100588482","NCT06941974","Partnering With Antenatal Navigators to Transform Health in Pregnancy","PATH","Inclusion Criteria:\n\n* Singleton gestation \\\u003C20 weeks of gestation\n* Nulliparous: no prior pregnancies ≥20 weeks excluding terminations\n* Low income (public insurance or residence in a neighborhood in which \\>10% of household incomes are \\\u003C125% of federal poverty line\n* Ability to speak and read English or Spanish\n* Established patient at one of practices associated with Northwestern Medical Group\n* Age 16 years or older\n\nExclusion:\n\n* Intent to transfer care to an outside institution\n* Prior enrollment in PATH\n* Concurrent enrollment in a study with competing aims\u002Fintervention","16 Years","50 Years",{"count":69,"type":21},600,"INTERVENTIONAL",[72],"NA","The Partnering with Antenatal Navigators to Transform Health in Pregnancy (PATH) study aims to evaluate whether an antenatal patient navigation program improves maternal health, neonatal health, pregnant women's experiences, and health care utilization outcomes among low-income pregnant women and their neonates. Patient navigation is an individualized, barrier-focused, longitudinal, patient-centered intervention that offers support for a defined set of health services. In this randomized controlled trial, pregnant women who are randomized to receive antenatal patient navigation will be compared to pregnant women who are randomized to receive usual care. Navigators will support pregnant women from before 20 weeks of gestation through 2 weeks postpartum. The PATH intervention will be grounded in understanding and addressing factors that influence health and access to care in order to promote self-efficacy, enhance access, and sustain long-term engagement.\n\nThe main objectives of the study are to:\n\n1. Evaluate whether PATH, compared to usual care, improves maternal health outcomes. We hypothesize the PATH model of antenatal patient navigation for low-income women will reduce the incidence of a composite of adverse maternal outcomes, all of which are known to be increased among women with barriers to care.\n2. Evaluate whether PATH, compared to usual care, improves perinatal health outcomes. We hypothesize PATH will reduce the incidence of a composite of adverse perinatal outcomes. We will also investigate neonatal\u002Fpediatric health care utilization.\n3. Evaluate patient, clinician, navigator, and healthcare system experiences with PATH in preparation for widespread implementation and dissemination of the PATH obstetric navigation model. This aim will be accomplished through investigating patient-reported outcomes, completing qualitative and process mapping interviews with navigated participants, and completing qualitative and process mapping interviews with clinicians, navigators, and health administrators.",[75,76,32,77,78],"Maternal Morbidity","Antenatal Health","Retention in Care","Prenatal Care","2026-04-02",{"date":81,"type":50},"2026-04-06",{"date":83,"type":50},"2025-10-06",{"date":85,"type":21},"2030-06-01",{"name":87,"class":57},"Northwestern University",1,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":97,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":70,"phases":102,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":88},"100587327","safeboosc-iiiv---does-cerebral-oximetry-monitoring-affect-renal-outcomes-100587327","NCT06926946","SafeBoosC-IIIv - Does Cerebral Oximetry Monitoring Affect Renal Outcomes","The Effects of Treatment Guided by Cerebral Oximetry Monitoring on Renal Outcomes in Invasively Mechanically Ventilated Neonates: an Ancillary Study of the SafeBoosC-IIIv Trial","SBIIIvR","Inclusion Criteria:\n\n* \\> 28 weeks of gestation Invasively ventilated\n\nExclusion Criteria:\n\n* major anomalies","ALL","1 Day","28 Days",{"count":101,"type":21},1000,[72],"Cerebral oximetry monitoring allows clinicians to optimize blood flow to the brain and oxygenation using the SafeBoosC treatment guideline. The guideline's interventions aims to stabilize blood pressure and oxygen levels.\n\nAs low blood pressure is a risk factor for the development of kidney injury, normalizing blood pressure may decrease the incidence of kidney injury in new-borns who are on ventilator.",[105,32],"Acute Renal Failure",[107,108,109,110,111],"Cerebral oximetry","NIRS","Neonate","Ventilated","Kidney injury","NOT_YET_RECRUITING","2025-07-17",{"date":115,"type":50},"2025-07-23",{"date":117,"type":21},"2025-07-31",{"date":119,"type":21},"2027-09-15",{"name":121,"class":57},"St. John's Research Institute"]